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Abstract
 
There is consensus that an optimized cancer vaccine will have to induce not only CD8
 
 
 
 cyto-
toxic but also CD4
 
 
 
 T helper (Th) cells, particularly interferon (IFN)-
 
 
 
–producing, type 1 Th
cells. The induction of strong, ex vivo detectable type 1 Th cell responses has not been re-
ported to date. We demonstrate now that the subcutaneous injection of cryopreserved, mature,
antigen-loaded, monocyte-derived dendritic cells (DCs) rapidly induces unequivocal Th1 re-
sponses (ex vivo detectable IFN-
 
 
 
–producing effectors as well as proliferating precursors) both
to the control antigen KLH and to major histocompatibility complex (MHC) class II–restricted
tumor peptides (melanoma-antigen [Mage]-3.DP4 and Mage-3.DR13) in the majority of 16
evaluable patients with metastatic melanoma. These Th1 cells recognized not only peptides,
but also DCs loaded with Mage-3 protein, and in case of Mage-3DP4–specific Th1 cells IFN-
 
 
 
was released even after direct recognition of viable, Mage-3–expressing HLA-DP4
 
 
 
 
 
melanoma
cells. The capacity of DCs to rapidly induce Th1 cells should be valuable to evaluate whether
Th1 cells are instrumental in targeting human cancer and chronic infections.
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Introduction
 
Active specific immunotherapy of cancer aims at generat-
ing strong tumor-specific T cell immunity. So far the focus
has been on inducing CD8
 
  
 
CTL responses (1, 2). Ample
evidence indicates, however, that CD4
 
 
 
 Th cells, particu-
larly IFN-
 
 
 
–producing Th1 cells, are another critical com-
ponent of an effective antitumor immune response (3–5) as
Th1 cells (i) help to initiate antigen-specific CD8
 
 
 
 T cells
(by expressing CD40L and activating dendritic cells [DCs]
 
*
 
via CD40), (ii) amplify and sustain CD8
 
 
 
 
 
T cell function
(by secreting cytokines such as IL-2), and (iii) can inhibit
tumor growth even in the absence of CD8
 
 
 
 T cells by re-
leasing IFN-
 
 
 
 (a macrophage activating and antiangioge-
netic cytokine; reference 6) or exerting direct cytotoxicity
independent of MHC class I molecules.
Tumor antigens and epitopes restricted by MHC class II
molecules (2–4) have recently been described so that it is
now possible to ask whether tumor-specific Th responses
can be induced in cancer patients by vaccination. We and
others have previously provided the proof of concept
that vaccination with mature monocyte-derived, peptide-
loaded DCs can expand tumor-specific CTL (7, 8). We
now wanted to explore whether such DCs would also be
able to induce tumor-specific Th1 cells as the crucial sec-
ond component of potent antitumor immunity. As in our
previous trials (9–11) we have chosen to study melanoma as
most MHC class I and class II–restricted tumor antigens
have been identified for this tumor.
DC vaccination induced unequivocal, melanoma-anti-
gen (Mage)-3 tumor peptide-specific effector as well as re-
call Th1 responses. This is to the best of our knowledge the
first time that ex vivo detectable Th1 cells specific for hu-
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man tumor antigens have been reproducibly induced in
human cancer patients by vaccination.
 
Materials and Methods
 
Clinical Protocol and Study Design.
 
We report here about the
first phase of a prolonged clinical trial in which five DC vaccina-
tions were administered subcutaneously at 14 d intervals followed
1 mo later by an evaluation. The study was approved by the Eth-
ics Committees and regulatory authorities, and informed written
consent was given by all patients. HLA-A1, -A2.1, and/or -A3
 
 
 
(as defined by serologic and molecular typing) patients suffering
from metastatic cutaneous melanoma (surgically incurable/no
longer curable distant or lymph node metastases; progression de-
spite standard surgical, radiation, chemotherapy, and/or immuno-
therapy) were eligible. Otherwise inclusion and exclusion criteria
(systemic chemo-, radio-, or immunotherapy 
 
 
 
4 wk before,
concomitant antitumor or immunomodulatory therapy, etc.)
were as described previously (9, 10).
 
DC Vaccine.
 
 Standardized DCs were generated from an ini-
tial leukapheresis (
 
 
 
10
 
10
 
 nucleated cells) essentially as described
previously (12, 13). In short, PBMCs isolated on Lymphoprep™
(Nycomed Pharma) were plated on Nunc Cell factories™ Nun-
clon™ culture flasks (Nalge Nunc International) in complete
medium, i.e., RPMI 1640 (GMP quality; BioWhittaker), 20 
 
 
 
g/
ml gentamicin, 2 mM glutamine, and 1% heat-inactivated autolo-
gous plasma. Adherent cells were cultured in 800 U/ml GM-CSF
(Leukomax™; Novartis) and 500 U/ml IL-4 (GMP quality;
CellGenix) for 6 d, then matured by adding 10 ng/ml TNF-
 
 
 
(GMP quality, a gift of Boehringer-Ingelheim), 10 ng/ml IL-1
 
 
 
(GMP quality; Amedak), 100 U/ml IL-6 (GMP quality; a gift
from Novartis), and 1 
 
 
 
g/ml prostaglandin E2 (Minprostin™;
Amersham Pharmacia Biotech and Upjohn). Mature DCs were
harvested on day 7, then frozen and stored in aliquots as described
previously (12). Release criteria for the DCs included typical
morphology (
 
 
 
95% nonadherent veiled cells), phenotype (
 
 
 
95%
HLA-DR
 
   
 
, CD86
 
   
 
, CD40
 
 
 
, CD25
 
 
 
, 
 
 
 
75% CD83
 
  
 
),
and negative microbial tests.
On the day of vaccination a DC aliquot was thawed and
loaded with several MHC class I and II–restricted peptides (3 h in
RPMI 1640 and 1% HSA), all in pharmaceutical quality (Clin-
alfa). Each of the individual five HLA-A1 (Mage-1, EADPT-
GHSY; Mage-3, EVDPIGHLY; Tyrosinase, KSDICTDEY;
FluNP, CTELKLSDY; and FluPB1, VSDGGPNLY), eight
HLA-A2.1 (Mage-4, GVYDGREHTV; Mage-10, GLYDG-
MEHL; GnTV, VLPDVFIRCV; Tyrosinase, YMDGTMSQV;
gp100, IMDQVPFSV; Melan-A, ELAGIGILTV; FluMP, GILG-
FVFTL; and FluBNP, KLGEFYNQMM), or three HLA-A3
(Mage-1, SLFRAVITK; gp100, LIYRRRLMK; and FluNP, IL-
RGSVAHK) restricted peptides was pulsed at 30 
 
 
 
M on separate
batches of 4 million DCs to avoid uncontrollable competition at
the MHC molecules. Thus, HLA-A1
 
 
 
 patients (15, 16, 27, 28),
A2.1
 
 
 
 patients (02, 12, 17, 19, 20, 21, 23) and A.3
 
 
 
 patients (05,
08, 10, 14, 18, 19, 27) received a total of 20, 32, and 12 million
DCs, respectively. One group (group A) of the MHC class
I–restricted peptides (HLA-A1–restricted FluNP, Mage-3; HLA-
A2.1–restricted FluMP, Melan-A, gp100, Mage-3; HLA-A3–
restricted FluNP, Mage-1) was pulsed onto DCs in the presence
of 100 ng/ml Rankl (reference 14; obtained from Cell Concepts
and biosafety tested in analogy to GMP guidelines) in uneven pa-
tients, without Rankl in even patients. Vice versa the residual
MHC class I peptides (group B) were pulsed in the presence of
Rankl in even patients, and without in uneven patients. This de-
 
sign was chosen to allow for a comparison of the influence of
Rankl pretreatment of the DCs on the induction of CTL re-
sponses with each patient serving as his own control. In case of
MHC class II–restricted peptides all DCs in all patients were
pulsed with 30 
 
 
 
g/ml Mage-3.DR13 (LLKYRAREPVTKAE;
reference 15) and Mage-3.DP4 (KKLLTQHFVQENYLEY)
peptides (16), while the two DR4-restricted MHC class II
peptides Tyrosinase (SYLQDSVPDSFQD; anchor-modified for
high-affinity binding to DR4) (17) and gp100 (WNRQLYPEW-
TEAQRLD; reference 18) were loaded only onto half of the
DCs (in analogy to the group A and B MHC class I–restricted
peptides, respectively) in order to avoid competition for the DR4
molecules. Peptide-loaded DCs were then collected, washed, and
administered (2 
 
 
 
 10
 
6
 
 DCs in 0.5 ml PBS and 1% HSA/site) by
superficial subcutaneous injection (i.e., at the dermis/subcutis
boundary) close to axillary or inguinal lymph nodes as described
previously (9, 10). Additionally, 4 million DCs (without any ex-
posure to Rankl) were loaded with KLH alone (by adding at day
5 of DC culture 10 
 
 
 
g/ml endotoxin-free keyhole limpet
hemocyanin; obtained from Calbiochem, and biosafety tested in
analogy to GMP guidelines), cryopreserved, thawed, and admin-
istered once at vaccination #1.
 
Measurement of Immune Responses.
 
Immediately before each
vaccination and 4 wk after vaccination #5 blood was drawn and
the fresh PBMCs were used for serial ex vivo ELISPOT analyses.
In addition, cryoconserved PBMCs prepared from the initial and
a second, smaller leukapheresis (performed 4 wk after vaccina-
tion #5 primarily for immunomonitoring) were thawed and as-
sayed simultaneously. All assays were done and evaluated in a
blinded fashion.
 
Measurement of Cytokine Releasing Effector CD4
 
 
 
 T Cell Re-
sponses in Uncultured PBMCs by ELISPOT Analysis.
 
PBMCs (in
select cases depleted from CD4
 
 
 
 or CD8
 
 
 
 
 
T cells by MACS
 
®
 
;
Miltenyi Biotec) were added in triplicates at 5 
 
 
 
 10
 
5
 
 cells per 96
wells precoated with anti–IL-2 (clone 5355.111; R&D Systems),
anti–IFN-
 
 
 
 (1-D1K; Mabtech), or anti IL-4 (MP4–25D2; BD
PharMingen) mAb. Then KLH or class II peptides were added at
10 
 
 
 
g/ml (peptides in select cases also at 1.0 and 0.1 
 
 
 
g/ml with
comparable results), and after 20 h (40 h for IL4) wells were
washed and incubated with biotinylated mAb to IL-2 (BAF 202;
R&D Systems), IFN-
 
 
 
 (7-B6–1; Mabtech), or IL-4 (12–1;
Mabtech) for 2 h. Final staining and computer assisted analysis
was done as described previously (9, 10). Background without
antigen was less than three spots (except where indicated), and
subtracted. Responses were considered significant if a minimum
of five spot-forming cells per well were detected, and addition-
ally, this number was at least twice that in negative control wells.
 
Measurement of Recall CD4
 
 
 
 T Cell Responses by Antigen-specific
Proliferation and ELISPOT Analysis.
 
Thawed PBMCs were
MACS
 
®
 
-depleted of CD8
 
 
 
 cells (in select examples of CD4
 
 
 
cells), and plated in triplicate at 2 
 
 
 
 10
 
5
 
 cells flat-bottomed, 96-
well in medium containing 10% heat inactivated human serum.
MHC class II tumor peptides were added at 10 
 
 
 
g/ml without
any cytokines. On day 4 
 
3
 
[H]-thymidine was added for 16 h.
KLH- and staphylococcal enterotoxin-proliferation were done as
described previously (9, 19). For some subjects CD4
 
 
 
 T cells
were isolated simultaneously from thawed pre- and posttherapy
(i.e., 4 wk after vaccination no. 5) PBMC aliquots by negative
magnetic bead selection (MACS
 
®
 
 kit; Miltenyi Biotec), then
stimulated once with autologous, peptide-loaded mature DCs (10
 
 
 
g/ml). On day 8 T cells were stimulated either with peptide
alone or with peptide-loaded DCs and IFN-
 
 
 
 spot-forming cells
were measured by ELISPOT. 
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Generation of CD4
 
 
 
 T Cell Clones.
 
 CD4
 
 
 
 T lymphocytes
(10
 
6
 
) isolated by MACS
 
®
 
 were cocultured with 30 
 
 
 
 10
 
3
 
 autolo-
gous peptide-pulsed (10 
 
 
 
g/ml, 3 h) and irradiated (100 Gy) ma-
ture DCs in 24-wells in 2 ml RPMI 1640 with 10% heat-inacti-
vated human serum. On day 3 IL-2 (50 U/ml) and IL-7 (10 ng/
ml) were added. On day 7 peptide-specific T cells were cloned
by limiting dilution. Stimulators were irradiated, peptide-pulsed
 
(1 h, 10 
 
 
 
g/ml) autologous EBV-B cells (5–10 
 
 
 
 10
 
3
 
 cells; round
bottomed, 96 well), while irradiated allogeneic LG2-EBV (5–10 
 
 
 
10
 
3
 
 cells per well) served as feeders. Weekly restimulations were
done with irradiated peptide-pulsed EBV-B cells in the presence
of IL-2 (50 U/ml) and feeder cells. 
 
Chromium Release and IFN-
 
 
 
 ELISA Assays.
 
Cr
 
51
 
 assays (4 h)
using autologous EBV-B cells (plus or minus transduction with
 
Table I.
 
Patient´s Characteristics, Status Before and Response to DC Vaccination
 
Metastases at study entry
Regional Distant
Patient
code
Sex
age Center
Previous
therapy Skin LN Skin LN Lung Liver Skeleton Others
Clinical
response
Fully evaluable patients (five vaccinations)
02 m-48 E S, ILP, IT, RT, CIT - - - - D/5 - - Pancreas 2/35 CR
05 f-77 E S, ILP, IT, RT, CT 6/34 ----- - S D
08 f-64 E S, IT, CIT, CT - - 1/3 1/4 - 2/80 - Muscle 1/60 OP
10 m-41 E S, IT - 2/13 - - - - - SD
12 f-65 E S, CT - - - 1/15 D/10 - - SD
14 m-58 E S, IT, CT - - - - D/25 - - OP
15 f-35 E S, CIT - 2/20 - - - - - SD
16 m-63 I S - 2/30 - 1/25 - - 1/20 OP
17 f-60 I S, CIT - - D/10 3/26 1/3 -
Kidney 2/15,
suprarenal 2/60 OP
18 m-77 I S - - - - 3/30 1/14 3/60 OP
19 m-70 E S, IT - - - - 9/25 - 2/25 OP
20 m-64 E S, IT, RT D (
 
 
 
50)/5 - D/5 - - - - SD
21 m-59 E S, IT - 2/9 - - - - - SD
23 f-36 E S, IT, CT 3/14 ----- - Intestine D SD
27 f-44 I S, IT - - - 1/51 1/16 - - SD
28 m-55 E S, CIT, ILP - 2/6 - 3/30 - - - OP
Not fully evaluable patients (less than five vaccinations)
01 f-29 E CIT - - - D/8 - 1/5 -
Spleen 3/35
peritoneum D
muscle 2/30
 
†
 
03 m-59 E S, IT, CT 1/70 D/15 - - - - -
Sinus cavernosus infiltration;
bone
 
†
 
04 f-55 E S, IT, CT - - D/30 - - - OP
07 f-48 I S, CIT, RT - 1/20 - D/50 - - - OP
09 m-57 E S, CIT 1/11 - - D - D -
Pancreas, duodenum,
gastric D OP
11 f-71 E S D (
 
 
 
50)/5 - - - - - OP
13 f-49 I S - - - D/35 - - - OP
24 f-37 I S, CT, IT, RT - - - 1/45 1/20 - - OP
Treatment Centers: E, Erlangen; I, Innsbruck.
Pretreatment therapy: IT, immunotherapy; C(I)T, chemo(immuno)therapy; S, surgery; RT, radiotherapy; ILP, isolated limb perfusion.
Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in mm); D, diffuse.
Clinical Response: CR, complete regression; OP, overall progression; SD, stable disease.
†Deceased. 
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retro-Ii.MAGE-3, plus or minus peptide loading at 10 
 
 
 
g/ml) as
targets were performed as described previously (16). The pMFG
retrovirus encoding Ii.MAGE-3 was constructed and used as de-
scribed previously (16). For IFN-
 
 
 
 assays 20-h supernatants of
EBV-B cell (20 
 
 
 
 10
 
3
 
)/CD4
 
 
 
 T cell (4 
 
 
 
 10
 
3 
 
cells) cocultures (96
well, 25 U/ml IL-2) were analyzed by ELISA (Biosource). To test
whether Th1 clones recognized autologous DCs loaded with
Mage-3 protein immature monocyte-derived DCs were incu-
bated overnight with 20 
 
 
 
g/ml protein Mage-3 (provided by
GlaxoSmithKline) or OVA (as a negative control) in the presence
of IL-1
 
 
 
, IL-6, PGE
 
2
 
, and TNF-
 
 
 
 to induce their maturation.
CD4
 
 
 
 T cell clones were then cocultured with 15 
 
 
 
 10
 
3
 
 protein-
loaded DCs in flat-bottomed microwells for 16 h and supernatants
analyzed by IFN-
 
 
 
 ELISA. To test whether the Th1 clones can
directly recognize tumor cells several MAGE-3–expressing mela-
noma cell lines (see Fig. 6), either HLA-DP4
 
 
 
 or HLA-DP4-,
were seeded at 15   103 cells per flat-bottomed microwell and in-
cubated for 48 h to allow the formation of a monolayer. CD4  T
cell clones were then added (4   103 cells per well) and superna-
tants analyzed by IFN-  ELISA after 16-h coculture. 
Delayed type hypersensitivity (DTH) was not part of the pro-
tocol but could be assessed in a few patients upon informed writ-
ten consent by intradermal injection at two sites of either 1.5  
105 peptide-loaded mature DCs or 50  g pure peptide in 0.1 ml
PBS/1%HSA per site. Negative controls were nonpulsed DCs
and vehicle.
Results
Patients and DC Vaccine. We report here about the first
phase (five biweekly vaccinations with peptide-loaded
DCs) of a prolonged and rather complex DC vaccination
trial. This first phase was designed to address the safety and
immunological efficacy of DC immunization to MHC class
II–restricted melanoma peptides. 28 patients (progressive
despite standard surgical, radiation, chemo-, and/or immu-
notherapy) with surgically incurable metastatic cutaneous
melanoma (22 with distant [patients 1–4, 6–9, 12, 13, 14,
16, 17, 18, 19, 20, and 23–28] and six with locoregional
metastases [05, 10, 11, 15, 21, 22]) were enrolled (Table I).
16 patients received five vaccinations and were fully evalu-
able (02, 05, 08, 10, 12, 14–21, 23, 27, and 28). Four pa-
tients had to be excluded before vaccination no. 1 as they
were not found eligible after prestudy screening (patients
06, 22, 25, and 26), two died before vaccination no. 2 and
3, respectively, (patients 01 and 03) and six patients (04, 07,
09, 11, 13, and 24) dropped out between vaccination no. 2
and 6 (patients 13 and 24 before no. 5; 04, 07, 09, 11 be-
fore no. 6) due to death or need for modification of ther-
apy (e.g., chemotherapy) because of progression. All DC
preparations fulfilled the release criteria.
Toxicity. No major ( grade II) toxicity was observed
in any patient. We noted, however, transient raise in body
temperature (38.8 C) in 5/16 fully evaluable patients (pa-
tients 08, 12, 15, 19, 23), and in 0/12 patients who were
not fully evaluable. In addition, strong ( 4 cm induration)
DTH reactions (Fig. 1 a) which first developed after the
second to fourth vaccination, and later increased to indura-
tions of up to 12 cm were observed at the vaccination sites
in the majority of patients (Fig. 1 a) (in all of the 16 fully
evaluable patients except 10, 14, 17, 19, and in five [04, 07,
09, 13, 24] of the seven patients who were not fully evalu-
able but had received at least two vaccinations). DTH reac-
tions to nonpeptide-pulsed DCs were negative or  1 cm.
This suggested induction of immunity to MHC class II
peptides as DTH assays typically detect primed Th cells. In-
deed, we found that unequivocal DTH reactions occurred
also in response to intradermally injected Mage-3 MHC
class II–restricted peptides (Fig. 1 b), and not only to DCs
carrying these peptides. Biopsies indicated a predominant
CD4  T cell infiltrate with only scattered CD8  T cells
(data not shown). DTH to intradermal peptides was not
part of the protocol, but in the three patients (positive
DTH in patients 12 and 08; Fig. 1 b; negative DTH in pa-
tient 04) that could be evaluated appeared to correlate with
induction of immunity (see below).
Immune Responses. A single injection of KLH-pulsed,
cryoconserved DCs rapidly induces KLH-specific Th1
cells. Each patient received (only) at vaccination no. 1 a
single subcutaneous injection of 4 million mature KLH-
pulsed monocyte-derived DCs as a positive control for the
functioning of the cryopreserved DCs, and to get an esti-
mate of the general competence of the patient’s immune
system to respond. Ex vivo ELISPOT assays performed 2
wk after the single injection of KLH-pulsed DCs revealed
that patients had rapidly developed Th1 type immunity
(Fig. 2 b and c), and a KLH-specific memory type response
was evident in antigen-specific proliferative assays per-
formed 3 mo after the single vaccination (Fig. 2 a). The
Th1 responses although detectable in all patients were vari-
able in strength. KLH-specific responses were mediated by
CD4  T cells, as evidenced by CD4  T cell depletion (data
not shown). The 12 patients who were not fully evaluable
(see Table I, and above) like the fully evaluable ones all had
a negative ELISPOT at onset, but those seven who re-
ceived vaccination no. 1 had developed KLH-specific Th1
cells 14 d after the single injection of KLH-loaded DCs
(patient 03: 82 IFN- /3 IL-4 spot-forming cells [SFC]; 04:
146 IFN- /13 IL-4 SFC; 07: 22 IFN- /1 IL-4 SFC; 09:
Figure 1. DTH reactions to peptide-loaded DCs and to Mage-3DP4
peptide alone. (a) Massive local reaction at the vaccination site to peptide-
loaded mature DCs in patient 12 ( 10 cm induration at 48 h), (b) DTH
reaction (arrows) to intradermally administered MAGE-3.DP4 peptide. No
DTH after injection of vehicle, MelanA.A2, or Mage-3.DR13 peptides.1283 Schuler-Thurner et al.
56 IFN- /2 IL-4 SFC; 11: 79 IFN- /1 IL-4 SFC; 13: 31
IFN- /5 IL-4 SFC, and patient 24: 30 IFN- /2 IL-4 SFC.
Interestingly, four additional melanoma patients who served
as controls and received a single subcutaneous injection of
KLH without DCs were not immunized to KLH indicat-
ing the adjuvant properties of DCs (Fig. 2 b and c).
Vaccination with Mage-3.DP4 or Mage-3.DR13 Tumor
Peptide-pulsed DCs Rapidly Induces a Th1 Effector Re-
sponse. Serial ex vivo ELISPOT analysis of blood freshly
drawn before each vaccination (i.e., 2 wk after the preced-
ing vaccination) as well as 4 wk after vaccination no. 5 re-
vealed that a Th1 type immune response was induced to
both Mage-3DP4 (Fig. 3 a and c) and Mage-3.DR13 pep-
tides (Fig. 3 b and d) in most patients (11/13 DP4  [84.6%]
and 10/10 DR13  or DR 15  [100%] patients, respec-
tively) and at all DC doses used (12   106: patients 05, 08,
10, and 18; 20   106: 15, 16, 27, and 28; 32   106: 02, 12,
17, and 19–23). The Th1 responses emerged rapidly, but
high and often plateau levels were reached only after a few
additional vaccinations (Fig. 4). Simultaneous Elispot analy-
ses of pre and postvaccination PBMC samples confirmed
the induction of Th1 responses, and depletion assays
showed that these were mediated by CD4  T cells (data not
shown). Interestingly, immunity to Mage-3.DP4 was also
induced in 1/2 HLA-DP4 negative, and to Mage-3.DR13
in 7/11 HLA-DR13 negative patients (Fig. 3). Remark-
ably, most (5/7) HLA-DR13 negative patients who got im-
munized to the Mage-3.DR13 peptide were HLA-DR15 .
Out of those six patients who were not fully evaluable but
received at least two vaccinations only patient 09 (DR13-,
DR15 , DP4 ) developed a positive Elispot (no positivity
before and after vaccination no. 1, but 77 Mage-3.DR13-
specific and 155 Mage-3.DP4-specific IFN-  spot-forming
cells after vaccination no. 2). Of note was also, that vaccina-
tion with Tyrosinase DR4 or gp100 DR4 peptide-loaded
DCs did not induce unequivocal immunity in any patient
including the four HLA-DR4  patients 10, 12, 14, and 20
(data not shown except examples in Fig. 4).
Vaccination with Mage-3DP4 or Mage-3.DR13 Tumor Pep-
tide-pulsed DCs Induces Th1 Recall Responses. Recall as-
says of batched pre and postvaccination PBMC samples
provided evidence for the expansion of Mage-3.DP4
and Mage-3.DR13–specific CD4  T cells, but not Tyrosi-
nase DR4 and gp100 DR4 peptide-specific ones (Fig. 5).
Mage-3 peptide-specific proliferative responses (cpm with
peptide   cpm without peptide) increased in 12/16 pa-
tients, whereby the responses were equivocal in two pa-
tients (08 and 28) due to an increased background postvac-
cination. Recall Elispot analyses were performed in select
patients, and confirmed the expansion of Mage-3 peptide-
specific CD4  T cells after vaccination, and showed that
they represented Th1 cells (Fig. 6).
The elicited Mage-3 peptide-specific Th1 cells release
IFN-  also in response to DCs loaded with Mage-3 pro-
tein and even after direct recognition of Mage-3 protein-
expressing HLA-DP4  tumor cells.
We next established several CD4  T cell clones from pa-
tients 12 and 15 (who exhibited particularly strong Th1 re-
sponses) to analyze the Th1 responses in more detail. Such
clones readily recognized Mage-3 protein processed by au-
tologous DCs (Fig. 7 a), and released large amounts of
IFN- . This proved their specificity for Mage-3, and indi-
cated their potential biological relevance. Mage-3.DP4
clones were special in that they were also able to directly
recognize autologous EBV-B cells transduced with retro-
Ii.Mage-3 (resulting in IFN-  release by the T cell clone
and lysis of the targets, data not shown), and were even ca-
pable of direct recognition of Mage-3 expressing, HLA-
DP4  (but not HLA-DP4-) melanoma cells (Fig. 7 b).
Figure 2. Priming to KLH after a single injection of KLH-pulsed DCs.
(a) Proliferation assay. Pre and postvaccination (i.e., before and 12 wk af-
ter the single injection of 4 million KLH-loaded DCs) PBMCs were
thawed, CD8 depleted, pulsed with KLH and proliferation simulta-
neously measured on day 5. For P1-P4 only Elispots were performed (see
b and c). SEM for measurements was  20%. This assay was performed in
parallel with the assay described in Fig. 5. (b and c) Ex vivo Elispot analy-
sis. KLH-specific IL-2 (b), IFN-  (c), and IL-4 (b and c) producing cells
from before and 14 d after DC immunization were quantified in freshly
isolated uncultured PBMCs. Patients P1 to P4 received a single subcuta-
neous injection of KLH (4 or 100  g) without DCs and were not primed
to KLH. SEM for measurements was  20%.1284 Induction of Type 1 T Helper Cells by Dendritic Cell Variation
Clinical Responses. At the evaluation 1 mo after the fifth
vaccination (i.e., 4 mo after the onset of the vaccinations)
seven of the fully evaluable patients (08, 14, 16, 17, 18, 19,
and 28) showed disease progression, eight (05, 10, 12, 15,
20, 21, 23, and 27) exhibited stable disease, and one patient
(02) had experienced complete regression of disease (me-
tastases in lung and pancreas).
Discussion
Active specific immunotherapy of cancer has focused so
far on the induction of CD8  CTL responses, primarily by
using MHC class I–restricted tumor peptides (most often in
the setting of melanoma as the prime model; references 1
and 2). Remarkably, CD8  effectors were detectable in
Figure 3. Induction of tumor-spe-
cific Th1 effector cells by DC immuni-
zation Mage-3.DP4 (a and c) and
Mage-3.DR13 (b and d) peptide-spe-
cific IL-2 (a and b), IFN-  (c and d),
and IL-4–producing cells were quanti-
tated every 14 d in freshly isolated un-
cultured PBMCs. Baseline spots (light
green and blue) and highest spot num-
bers (dark green and blue) reached
upon DC vaccination are shown. Patient
02 was not vaccinated to Mage-3DP4
peptide so that the respective data are
missing. IL-4 spot-forming cells were
in general  25% of the IL-2 and IFN- 
ones, and are not shown. Background
without antigen was subtracted and was
less than three spots for all cytokines
measured throughout the study (ex-
cept for patient 28 with nine spots
background postvaccination). Patients
are grouped on the x-axis according
to their expression of HLA.DP4,
.DR13, or .DR15. SEM for measure-
ments was  25%.
Figure 4. Kinetics of tumor-
specific Th1 effector induction
PBMCs of patients were serially
tested every 14 d by ex vivo
Elispot analysis as in Fig. 3 to
quantitate the IL-2 and IFN- –
producing cells specific for
Mage-3DP4, Mage-3DR13,
gp100DR4, and TyrosinaseDR4
(Tyr.DR4) peptides. Results are
shown for four representative
subjects (HLA-DR4 /DP4  pa-
tients 10 and 12, HLA-DR13 /
DP4  patients 08 and 15) Back-
ground without antigen was sub-
tracted and was less than three
spots at all time points. SEM for
measurements was  25%.1285 Schuler-Thurner et al.
blood directly ex vivo only after administration of such
peptides on DCs, while in vitro restimulations were re-
quired for their detection after peptide vaccination (10, 20,
21, for review, see references 2 and 7). The induction of
tumor-specific CD4  Th cells has so far been tried prima-
rily by peptide vaccination albeit with limited success (2–5).
Even in the most convincing studies reported to date (22,
23) such Th cell responses were neither shown to be de-
tectable ex vivo nor to be of the desired Th1 type. This ap-
Figure 5. Induction of tumor-specific recall Th responses by DC
immunization pre- and post therapy (i.e., 4 wk after vaccination no. 5)
PBMCs were thawed, CD8 depleted, pulsed with gp100 DR4, tyrosinase
DR4, Mage-3.DP4, and Mage-3.DR13 peptides and proliferation mea-
sured on day 5. In parallel cultures SEA (staphylococcal enterotoxin A)
was added as a control both for the functioning of CD4  T cells and an
enhanced background reactivity, and proliferation measured on day 3.
The results shown represent the average cpm 3[H]thymidine incorpora-
tion) and SEM of triplicate cultures. An increased proliferative response to
Mage-3 peptide is seen in 12/16 patients but is ambiguous in patients 08
and 28 due to an increased background postvaccination.
Figure 6. Induction of tumor-specific recall Th1 responses by DC im-
munization Pre and posttherapy (i.e., 4 wk after vaccination no. 5) CD4  T
cells from patients 12 (a) and 15 (b) were stimulated once in vitro with au-
tologous, peptide-loaded mature DCs (10  g/ml). On day 8 T cells were
stimulated either with peptide alone (Mage-3.DP-4 or Mage-3.DR13 pep-
tide) or with peptide-loaded mature DCs and IFN-  spot-forming cells
were measured by the Elispot technique. The results shown represent the
average and SD of triplicate cocultures. Note that Mage-3.DP4-specific and
Mage-3.DR13-specific IFN-  spot-producing CD4  Th1 cells are clearly
expanded after DC vaccination in patients 12 and 15, respectively which
fits to the results of the respective proliferative assays (Fig. 5). Note also that
(auto-) reactivity to peptide-unloaded DCs (generated in patient 12 from
post, and in patient 15 from prevaccination PBMCs) is not increased, but
rather decreased upon DC vaccination and induction of specific immunity.1286 Induction of Type 1 T Helper Cells by Dendritic Cell Variation
plies also to antiidiotype-specific T cell proliferative re-
sponses that have been induced in B cell lymphoma by
vaccination with idiotype protein and KLH as adjuvant
(24). Such antiidiotype responses have also been reported
after vaccination with idiotype-pulsed DCs (25 and 26), but
in these studies idiotype protein was simultaneously admin-
istered also subcutaneously with KLH so that the role of
DC vaccination for the induction of the antiidiotype re-
sponses is unclear. Therefore, we wanted to learn whether
DCs would be valuable adjuvants for the induction of
CD4  helper responses, notably of the desired Th1 type to
genuine human tumor antigens. We found that the subcu-
taneous injection of mature, cryopreserved, peptide-loaded,
monocyte-derived DCs rapidly induces tumor-specific Th1
cells that are readily detectable in fresh blood without re-
stimulation in the majority of metastatic melanoma patients
including those with a heavy tumor load. Several additional
specific observations made in our study appear noteworthy. 
The single subcutaneous injection of 4 million KLH-
pulsed DC-induced unambiguous Th1 responses (prolifer-
ating memory cells as well as ex vivo detectable IFN- –
producing effectors) in most patients. This rapid induction
of a Th1 response by DCs matured by IL-1 , TNF- ,
IL-6, and PGE2 was most noteworthy as it clearly contra-
dicted the results of in vitro experiments predicting that
such DCs would release little measurable p70 (27) and,
therefore, induce Th2 and not Th1 responses (28, 29).
The demonstration that monocyte-derived DCs that are
generated under the aegis of GM-CSF and IL-4 from
apheresis products, matured by a defined cocktail (IL-1 ,
TNF- , IL-6, PGE2) and cryopreserved according to our
recently described method (12) are functional in vivo is
important as cryopreserved, antigen-preloaded, mature
DC aliquots bear obvious logistical advantages. Of note is
also that immunization to KLH occurred even in Multi-
test Merieux negative patients (anergic: 04, 05, 08, 12, 13,
17, and 27; hypoergic: 02, 03, 07, 09, 14, 18, 19, 20, and
24; normergic: 10, 11, 15, 16, 21, 23, and 28). It will be
interesting to test in future studies whether the intensity
and/or quality of immune responses following DC-medi-
ated sensitization to KLH and/or another control antigen
will be a useful parameter for predicting whether antitu-
mor responses can be expected.
With respect to the induction of ex vivo detectable tu-
mor-specific Th1 responses again several observations were
notable besides the mere fact that to the best of our knowl-
edge such induction has not previously been reported. Im-
mune responses to the Mage-3DP4 and DR13 peptides
were remarkable in strength and quality, particularly as they
occurred also in patients whose metastases expressed Mage-3
(data not shown) and thus could have tolerized to Mage-3.
IFN- –producing Mage-3 specific Th1 effectors were also
absent in all patients at onset, but became readily detectable
upon a few vaccinations by ex vivo Elispot analysis. This is
noteworthy given the fact that spontaneously occurring tu-
mor-specific CD4  T cell responses appear to be detectable
only after repetitive in vitro stimulations in the presence of
cytokines (3–5, 15–18). Recall assays indicated that DC
vaccination had also induced proliferating Mage-3 peptide-
specific Th cells. The proliferative responses were detect-
able even though no cytokines were added and cells were
stimulated only once. The Mage-3DP4–specific CD4  T
cells were not only able to produce IFN-  but also lysed
autologous EBV-B cells when loaded with Mage-3DP4
peptide or transfected with Ii.Mage-3 to generate Mage-3/
HLA-DP4 complexes by natural processing. Other experi-
ments indicated that the Mage-3DP4-specific CD4  T
cells release IFN-  also after recognition of either Mage-
3 /HLA-DP4  melanoma cells or DCs that had taken up
and processed Mage-3 protein. Ongoing experiments also
demonstrate the recognition of DCs that have processed
necrotic, Mage-3–expressing melanoma cells. This clearly
illustrates the potential biological relevance of these Th
cells in the microenvironment of the tumor as based on the
in vitro properties they should also be able to take up and
process Mage-3 protein that is released from tumor cells af-
ter their lysis by CTLs. This assumption is supported by
the finding that the regressing metastases which we could
study so far were infiltrated both by CD8  and CD4  T
cells.
Figure 7.  Mage-3.DP4-spe-
cific Th clones recognize autolo-
gous DCs that have processed
Mage-3 protein and even di-
rectly recognize Mage-3 express-
ing, HLA-DP4  melanoma
cells. (a) Autologous, immature
monocyte-derived DCs were
loaded with Mage-3 protein or
OVA (as a negative control) dur-
ing their maturation, then 15  
103 mature, protein-loaded DCs
were cocultured with CD4  T
cell clone R12–57 (4   103 cells
per 96 well), and after 16 h
IFN-  was measured in the su-
pernatants. (b) In a parallel set of experiments CD4  T cell clone R12–57 (4   103 cells per 96 well) was added to monolayers of several Mage-3 express-
ing melanoma cell lines, either HLA-DP4  or HLA-DP4-, and IFN-  assayed by ELISA in 16 h supernatants. Data are triplicate values. SEM was  15%,
bars. Several clones of patients 12 and 15 were tested with identical results.1287 Schuler-Thurner et al.
In contrast to the unambiguous induction of Th1 re-
sponses to Mage-3 peptides we found no immunization to
the HLA-DR4–restricted gp100 and Tyrosinase (anchor-
modified for high-affinity binding to DR4) melanoma pep-
tides, possibly simply because only four patients (no. 10,
12, 14, and 20) were HLA-DR4 . Besides the small sample
size the fact that these DR4 peptides were loaded on to half
of the DCs (to avoid competition for DR4 molecules)
while the others were loaded on to all DCs, competition
by T cells specific for the Mage-3 versus tyrosinase/gp100
peptides at the level of the presenting DCs, and major dif-
ferences in precursor frequencies are other testable explana-
tions. As it is well known that MHC class II–restricted pep-
tides might bind to several different class II molecules (30)
we had loaded them onto the DCs irrespective of the actual
expression of the restricting MHC class II molecule. In-
deed, 1/2 HLA-DP4 negative patients also developed
Mage-3DP4–specific Th1 cells. A more striking finding
was, that the majority (11/16) of the fully evaluable pa-
tients who were immunized to the Mage-3DR13 peptide
were actually HLA-DR13 negative, and that 5/11 ex-
pressed HLA-DR15. Interestingly, the binding specificity
for HLA-DRB1*1501 has been found to be an L, V, or I in
the relative position 1, an F, Y, or I in the relative position
4 and an I, L, V, M, or F in the relative position 7 (31).
Comparing the amino acid sequence of the MAGE-
3DR13 peptide (LLKYRAREPVTHAE) with this binding
motif suggests good binding to HLA-DRB1*1501 as there
is an L in position 1 and an Y in position 4. Interestingly,
an overlapping binding repertoire of DR13 and DR15 has
already been described previously (30). The fine specificity
of Th1 clones that recognize the Mage-3 peptides will be
the subject of further studies.
The current clinical trial was designed to clarify in the
first phase (five biweekly vaccinations followed by a clinical
evaluation 1 mo later, i.e., 3 mo after vaccination no. 1)
whether tumor peptide–specific Th1 responses can be in-
duced by DC vaccination without significant toxicity, and
we report here that the answer to this question is yes. After
conclusion of the second, currently ongoing period of pro-
longed vaccinations we will be in a position to address addi-
tional important questions, in particular whether the induc-
tion of tumor-specific Th1 cells (which appear to be
maintained so far) correlates with the induction and longev-
ity of CTL responses and clinical efficacy. It will also be in-
teresting to study whether tumor-specific Th1 cells will di-
rect any emerging humoral antitumor responses (32) to the
IgG1 subclass of antibodies which might be of therapeutic
value by their ability to fix complement and to bind
to macrophage Fc receptors. As half of the MHC class
I–restricted peptides have been administered on DCs pre-
treated with Rankl (14) (a molecule identical to TRANCE;
reference 33) it will also be possible to determine whether
the respective CTL responses are markedly enhanced. Given
the large number of MHC class I peptides used (Materials
and Methods) we will perform a simultaneous analysis of
blood samples taken at selected time points as soon as pa-
tients have been followed for at least 1 y. Interestingly, cur-
rently all patients (except patient 05) who were responders
at 4 mo (one patient [02] with complete regression, eight
with stable disease) continue to respond, and two of these
stable patients have now almost cleared their metastases. 
The finding that DC vaccination besides inducing tu-
mor-specific CTL (7, 8) can also readily induce ex vivo de-
tectable human tumor peptide-specific Th1 immune re-
sponses underscores the potent adjuvant properties of DCs,
and encourages further optimization of this novel immuni-
zation approach. Th1 induction by DCs should be valuable
to explore the factual role of Th1 cells for vaccines target-
ing cancer, chronic viral and intracellular infections (2–5),
and possibly Th2-mediated diseases (34).
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